Rat Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer Protein, His Tag&Tag Free (MALS verified)

用户评价
货号-规格
价格
Qty.
IT8-R52E1-100ug
¥4305.00
IT8-R52E1-1mg (500ug X 2)
¥30240.00
合计0件 产品金额¥ 0

产品详情

  • 分子别名(Synonym)

    Integrin alpha V beta 8, ITGAV&ITGB8

  • 表达区间及表达系统(Source)

    Rat Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer, His Tag&Tag Free (IT8-R52E1) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Pro 988 & Gly 22 - Ser 679 (Accession # NP_001385621.1 & A0A0G2JVU1).

    Predicted N-terminus: Phe 31 | Gly 22

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    Integrin alpha V beta 8 Structure

    Rat ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free, produced by co-expression of ITGAV and ITGB8, has a calculated MW of 113 kDa (ITGAV) & 77 kDa (ITGB8). Subunit ITGAV is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and subunit ITGB8 contains no tag but a basic tail at the C-terminus. The protein migrates as 125-145 kDa (ITGAV) and 75-85 kDa (ITGB8) under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • 内毒素(Endotoxin)

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • 纯度(Purity)

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

数据展示

  • 电泳(SDS-PAGE)

    Integrin alpha V beta 8 SDS-PAGE

    Rat Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer, His Tag&Tag Free on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    Integrin alpha V beta 8 SEC-MALS

    The purity of Rat Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer, His Tag&Tag Free (Cat. No. IT8-R52E1) is more than 90% and the molecular weight of this protein is around 200-230 kDa verified by SEC-MALS.

    Report
  • 活性(Bioactivity)-ELISA

     Integrin alpha V beta 8 ELISA

    Immobilized Rat Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer, His Tag&Tag Free (Cat. No. IT8-R52E1) at 5 μg/mL (100 μL/well) can bind Biotinylated Human Latent TGF-Beta 1, His,Avitag (Cat. No. TG1-H82Qb) with a linear range of 0.2-13 ng/mL (QC tested).

    Protocol
  •  Integrin alpha V beta 8 ELISA

    Immobilized Rat Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer, His Tag&Tag Free (Cat. No. IT8-R52E1) at 5 μg/mL (100 μL/well) can bind Biotinylated Human Vitronectin with a linear range of 0.1-3 ng/mL (Routinely tested).

    Protocol

用户评价
发表评论

背景介绍

Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.

前沿进展

 
药物研发进展
  • 英文全称:

    integrin alpha V/beta 8

  • 中文全称:

    整合素α-v/β-8复合体

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    2 详情

  • 最高研发阶段:

    临床二期

联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价
  • 背景介绍